NCT06128343 Anatomical-Clinical Base of Adenocarcinoma Pancreatic
| NCT ID | NCT06128343 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Toulouse |
| Condition | Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2023-11-16 |
| Primary Completion | 2035-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2023-11-16 with a primary completion date of 2035-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
BACAP-2 is a prospective biobank dedicated to the pancreatic adenocarcinoma including clinical data and biological samples from tumor. The aim is to enrich the previous propective collection BACAP in order to support future research projects.
Eligibility Criteria
Inclusion Criteria: * Patient with pancreatic mass syndrome explored by ultrasound endoscopy with cytopuncture or * Patient with pancreatic mass syndrome explored by an abdominal scanner with and without injection of product contrast and/or puncture of the mass or secondary lesions by radiological route or * Patient with pancreatic adenocarcinoma proven histologically and/or cytologically Exclusion Criteria: * Patient with a pancreatic tumor whose analysis histological is not an adenocarcinoma * Pregnant or breastfeeding patient
Contact & Investigator
Barbara BOURNET, MD, PhD
PRINCIPAL INVESTIGATOR
University Hospital, Toulouse
Frequently Asked Questions
Who can join the NCT06128343 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 120 Years, studying Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06128343 currently recruiting?
Yes, NCT06128343 is actively recruiting participants. Contact the research team at bournet.b@chu-toulouse.fr for enrollment information.
Where is the NCT06128343 trial being conducted?
This trial is being conducted at Béthune, France, Bordeaux, France, Lille, France, Lyon, France and 4 additional locations.
Who is sponsoring the NCT06128343 clinical trial?
NCT06128343 is sponsored by University Hospital, Toulouse. The principal investigator is Barbara BOURNET, MD, PhD at University Hospital, Toulouse. The trial plans to enroll 1,500 participants.